Get the StoQuant digest — free
Free StoQuant digest by email. No account needed.
See today's research picks.
GSK vs NVCR — Stock Comparison
Compare GSK and NVCR side-by-side on StoQuant: GSK Q-Score 47 vs NVCR 50; analyst signal 52 vs 58. Plus alt data signals, insider buying, catalysts, strategic edges, short interest, social sentiment, and macro context.
Side-by-side snapshot
- GSK — GSK plc · Health Care · market cap $102.12B · Q-Score verdict Hold (47.0, grade C) · analyst signal 52/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: technicals 51/100, ML forecast 23/100 · weakest signals: analyst consensus 22/100. Full GSK research.
- NVCR — NOVOCURE LTD · Health Care · Q-Score verdict Hold (50.0, grade C) · analyst signal 58/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: competitive moat 81/100, valuation 77/100 · weakest signals: earnings quality 45/100, technicals 29/100. Full NVCR research.
What you can compare
- Q-Score: StoQuant's composite 0–100 rating based on 140+ financial signals.
- Alt data signals: Google Trends, EDGAR 8-K filings, job postings, and more.
- Insider activity: Cluster scores and recent Form 4 buying.
- Catalysts: Earnings, analyst changes, M&A, clinical trials, and SEC events.
- Strategic edges: Competitive moat and durable advantage analysis.
- Short interest & social sentiment: Short % float, social mention volume, and bullish/bearish breakdown.
- Macro context: Market regime and sector rotation alignment.
Deep dive: GSK research · NVCR research. Sign in to StoQuant to run live comparisons for any tickers. Sign up free →
Register founding interest — Pro $29/mo or Power $79/mo
Paid plans aren’t for sale yet. Leave your email to lock founding pricing (Pro $29, Power $79); we’ll reach out personally.